Cargando…

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma

INTRODUCTION: The PD-1 inhibitors have shown good response in the treatment for many types of malignant tumors, but as monotherapy for advanced esophageal squamous carcinoma, the objective response rate is low. Here we report a case of the patient with advanced esophageal squamous cell carcinoma (ES...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yong, Ou, Zhu’an, Yao, Zhifang, Qiao, Guibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783208/ https://www.ncbi.nlm.nih.gov/pubmed/31577707 http://dx.doi.org/10.1097/MD.0000000000017164

Ejemplares similares

Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
por: Zhang, Pin-Liang, et al.
Publicado: (2019)

Predictive value of microvascular density for response to anlotinib in advanced NSCLC
por: Liu, Danqing, et al.
Publicado: (2022)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report
por: Zhang, Aixia, et al.
Publicado: (2019)

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition
por: Swed, Brandon, et al.
Publicado: (2021)

Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021)

Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review
por: Song, Wenjing, et al.
Publicado: (2020)

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Orbital adenoid cystic carcinoma treated by radiotherapy combined with anlotinib in a 13-year-old girl: A case report
por: Wu, Xue, et al.
Publicado: (2023)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report
por: Pi, Guoliang, et al.
Publicado: (2016)

Real-world treatment patterns and survival for locally advanced esophageal squamous cell carcinoma
por: Luo, Hua-Chun, et al.
Publicado: (2023)

Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2014)

Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma
por: Zhang, Guoqing, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma
por: Qiu, Xiangnan, et al.
Publicado: (2020)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

High expression of PDGFA predicts poor prognosis of esophageal squamous cell carcinoma
por: Han, Na, et al.
Publicado: (2021)

Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma
por: Zhou, Lu, et al.
Publicado: (2023)

Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma: A case report and review of the literature
por: Liu, Lei, et al.
Publicado: (2020)

Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan
por: Chen, Hui-Shan, et al.
Publicado: (2016)

Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma
por: Yan, Li, et al.
Publicado: (2020)

High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma
por: Ma, Junliang, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
por: Pu, Dan, et al.
Publicado: (2020)

Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report
por: Hean, Virginie, et al.
Publicado: (2021)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma
por: He, Xiao, et al.
Publicado: (2019)

A nomogram based on hematological markers to predict radiosensitivity in patients with esophageal squamous cell carcinoma
por: Sun, Lijun, et al.
Publicado: (2023)

Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs
por: Hirata, Aya, et al.
Publicado: (2021)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

High-dose radiation therapy alone by moderate hypofractionation for patients with thoracic esophageal squamous cell carcinoma
por: Oh, Dongryul, et al.
Publicado: (2016)

Microvessel density as a prognostic factor in esophageal squamous cell cancer patients: A meta-analysis
por: Ma, Guangzhi, et al.
Publicado: (2017)

High expression of cytokeratin CAM5.2 in esophageal squamous cell carcinoma is associated with poor prognosis
por: He, Shujin, et al.
Publicado: (2019)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety
por: Ye, Haiyong, et al.
Publicado: (2021)

The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
por: Shi, Zuolin, et al.
Publicado: (2022)

Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis
por: Zhou, Rui, et al.
Publicado: (2020)

Postoperative radiotherapy for the young–old patients with thoracic esophageal squamous cell carcinoma: A 2-center experience
por: Ding, Wei, et al.
Publicado: (2020)

The role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in esophageal squamous cell carcinoma
por: Bao, Junhui, et al.
Publicado: (2020)

Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma
por: Guo, Quanquan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0fnu8red3fsv45hvqnrun4obt0